Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

DYN

Dyne Therapeutics Inc

May 17 • 04:00PM ET

27.68

Dollar change -1.07
Percentage change -3.72	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB SCHA LABU VTWO IWO DWAS

Index	RUT	P/E	-	EPS (ttm)	-3.97	Insider Own	34.22%	Shs Outstand	61.47M	Perf Week	6.46%
Market Cap	2.25B	Forward P/E	-	EPS next Y	-3.32	Insider Trans	-10.69%	Shs Float	53.39M	Perf Month	17.04%
Income	-257.40M	PEG	-	EPS next Q	-0.75	Inst Own	82.59%	Short Float	18.04%	Perf Quarter	20.82%
Sales	0.00M	P/S	-	EPS this Y	21.41%	Inst Trans	-3.15%	Short Ratio	7.78	Perf Half Y	154.41%
Book/sh	5.49	P/B	5.04	EPS next Y	-7.06%	ROA	-63.48%	Short Interest	9.63M	Perf Year	103.98%
Cash/sh	5.59	P/C	4.95	EPS next 5Y	-	ROE	-71.50%	52W Range	6.40 - 30.27	Perf YTD	108.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-106.26%	ROI	-51.49%	52W High	-8.55%	Beta	1.02
Dividend TTM	-	Quick Ratio	21.83	Sales past 5Y	0.00%	Gross Margin	-	52W Low	332.50%	ATR (14)	1.59
Dividend Ex-Date	-	Current Ratio	21.83	EPS Y/Y TTM	-18.88%	Oper. Margin	0.00%	RSI (14)	56.91	Volatility	6.38% 5.67%
Employees	141	Debt/Eq	0.06	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	39.22
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	-3.25%	Payout	-	Rel Volume	1.06	Prev Close	28.75
Sales Surprise	-100.00%	EPS Surprise	-1.25%	Sales Q/Q	-	Earnings	May 02 AMC	Avg Volume	1.24M	Price	27.68
SMA20	6.73%	SMA50	4.49%	SMA200	66.38%	Trades		Volume	1,318,228	Change	-3.72%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	H.C. Wainwright	Buy	$36
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy	$16 → $27
Feb-15-23	Initiated	Oppenheimer	Outperform	$34
Jan-26-23	Initiated	Guggenheim	Buy	$33
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$17
Jul-12-22	Initiated	Raymond James	Outperform	$15
Oct-12-20	Initiated	Stifel	Buy	$29
Oct-12-20	Initiated	Piper Sandler	Overweight	$34
Oct-12-20	Initiated	JP Morgan	Overweight	$27
Oct-12-20	Initiated	Jefferies	Buy	$47

Show Previous Ratings

May-04-24 05:31AM	Dyne Therapeutics Inc (DYN) Q1 2024 Earnings: Aligns with Analyst Projections (GuruFocus.com)
May-02-24 11:52PM	DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:10PM	Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-30-24 07:32AM	Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target (MT Newswires)
Mar-27-24 04:05PM	Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer (GlobeNewswire) +6.42%
08:30AM	Loading…
08:30AM	Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium (GlobeNewswire)
Mar-25-24 12:28PM	United Airlines, Dyne Therapeutics fall; Lucid Group, Century Aluminum rise, Monday, 3/25/2024 (Associated Press Finance) -7.72%
07:30AM	Dyne Therapeutics Announces CEO Transition (GlobeNewswire)
Mar-13-24 07:30AM	Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days (GlobeNewswire)
Mar-07-24 01:19PM	Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ... (GuruFocus.com)
Mar-05-24 10:53AM	DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.64%
07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-02-24 12:00AM	CEO & President Joshua Brumm Sells 100,000 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) +7.69%
Feb-14-24 04:15PM	Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire)
07:30AM	Loading…
Feb-01-24 07:30AM	Dyne Therapeutics to Present at February Investor Conferences (GlobeNewswire)
Jan-26-24 11:01PM	Chief Business Officer Jonathan Mcneill Sells 20,000 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com) +18.21%
Jan-22-24 10:14PM	7 Speculative Stocks to Double Your Money THIS Year (InvestorPlace)
Jan-12-24 01:12PM	Hedge Fund and Insider Trading News: Steve Cohen, Crispin Odey, Bill Ackman, Saba Capital Management, Moab Capital Partners, Eisler Capital, Dyne Therapeutics Inc. (DYN), and More (Insider Monkey)
Jan-11-24 04:05PM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire) -5.36%
Jan-05-24 09:02AM	CEO & President Joshua Brumm Sells 269,719 Shares of Dyne Therapeutics Inc (DYN) (GuruFocus.com) -7.37%
07:30AM	Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-04-24 10:46PM	Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock (GlobeNewswire) +31.28%
04:37PM	Todays Stock Market Movers: Walgreens, Mobileye, Apple, APA, Callon, Peloton, Sunrun, and More (Barrons.com)
12:39PM	These Stocks Are Moving the Most Today: Walgreens, Mobileye, Apple, APA, Callon, Peloton, Sunrun, and More (Barrons.com)
Jan-03-24 04:25PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +13.09%
02:46PM	Biotech Stocks Dyne, Agios Leap on Muscle-Disorder Drugs' Trial Results (The Wall Street Journal)
02:01PM	Biotechs Dyne, Agios Leap on Muscle-Disorder Drugs Trial Results (The Wall Street Journal)
08:19AM	Why Is Dyne Therapeutics (DYN) Stock Up 39% Today? (InvestorPlace)
06:30AM	Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE Platform in Developing Therapeutics for Rare Muscle Diseases (GlobeNewswire)
04:05PM	Loading…
Jan-02-24 04:05PM	Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials (GlobeNewswire)
Nov-13-23 06:59PM	3 of the Best Cheap Stocks Under $20 to Buy Now: November Edition (InvestorPlace)
Nov-07-23 07:30AM	Dyne Therapeutics to Present at November Investor Conferences (GlobeNewswire) +14.58%
Oct-31-23 05:36AM	Dyne Therapeutics Inc (DYN) Reports Q3 2023 Financial Results and Progress in Clinical Trials (GuruFocus.com)
01:11AM	The Dyne Therapeutics Inc (DYN) Company: A Short SWOT Analysis (GuruFocus.com)
Oct-30-23 07:30AM	Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones (GlobeNewswire) +10.57%
Sep-28-23 07:30AM	Dyne Therapeutics to Present at October Investor Conferences (GlobeNewswire)
Sep-20-23 04:05PM	Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire) -5.48%
Sep-15-23 01:52PM	Why Shares of Dyne Therapeutics Fell This Week (Motley Fool)
Sep-14-23 01:22PM	Insider Sell: Chief Medical Officer Wildon Farwell Sells 1,707 Shares of Dyne Therapeutics Inc (GuruFocus.com)
Sep-05-23 07:30AM	Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Aug-03-23 07:30AM	Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Jun-16-23 08:46AM	SMID Caps Are Poised for a Good Run, Says Oppenheimer And These 2 Stocks Fit the Bill With Over 100% Upside (TipRanks) -9.50%
Jun-01-23 07:30AM	Dyne Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-25-23 07:30AM	Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101 (GlobeNewswire) -7.56%
May-17-23 11:25AM	We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate (Simply Wall St.)
07:30AM	Dyne Therapeutics Preclinical Data Demonstrating FORCE Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting (GlobeNewswire)
May-11-23 07:30AM	Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
May-03-23 07:35AM	Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference (GlobeNewswire)
May-02-23 04:46PM	Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE Platform Delivery to CNS (GlobeNewswire)
Mar-23-23 07:30AM	Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-20-23 07:30AM	Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference (GlobeNewswire)
Mar-07-23 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-02-23 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire) +5.06%
Mar-01-23 09:00AM	How to chart anchored VWAP multiple time frames: Brian Shannon, CMT (Yahoo Finance Video) +5.82%
Feb-27-23 04:40PM	Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock (Benzinga) +12.76%
Feb-05-23 05:03AM	TipRanks Perfect 10 List: Strong Catalysts Confirm the Bull Thesis on These 2 Stocks (TipRanks)
Jan-19-23 08:23AM	Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics (Zacks)
Jan-18-23 08:49AM	5 Stocks to Buy as the Drug Industry Bets Big on Innovation (Zacks)
Jan-10-23 12:00PM	All You Need to Know About Dyne Therapeutics, Inc. (DYN) Rating Upgrade to Strong Buy (Zacks)
Jan-03-23 07:30AM	Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-22 09:55AM	Does Dyne Therapeutics, Inc. (DYN) Have the Potential to Rally 84% as Wall Street Analysts Expect? (Zacks)
Dec-09-22 09:55AM	Here's Why Dyne Therapeutics, Inc. (DYN) Is a Great 'Buy the Bottom' Stock Now (Zacks) -5.05%
Dec-08-22 08:10AM	Will Dyne Therapeutics (NASDAQ:DYN) Spend Its Cash Wisely? (Simply Wall St.)
Nov-30-22 09:55AM	Wall Street Analysts Predict a 141% Upside in Dyne Therapeutics, Inc. (DYN): Here's What You Should Know (Zacks) +8.43%
Nov-03-22 07:30AM	Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) +9.63%
Nov-02-22 07:30AM	Dyne Therapeutics to Present at Investor Conferences in November (GlobeNewswire)
Oct-31-22 07:30AM	Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Oct-12-22 06:45AM	Dyne founder heads up new RNA-editing startup (American City Business Journals)
Oct-11-22 04:10PM	Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress (GlobeNewswire)
Sep-27-22 07:30AM	Dyne Therapeutics to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire) -9.57%
Sep-12-22 07:00AM	Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During Spotlight on the Clinic Virtual Event (GlobeNewswire)
Sep-06-22 04:30PM	Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire) +5.32%
07:01AM	Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
07:00AM	Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Aug-29-22 07:30AM	Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development (GlobeNewswire)
Aug-10-22 07:30AM	Dyne Therapeutics Announces Breakthrough Article Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research (GlobeNewswire) +7.75%
Aug-04-22 07:30AM	Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Jul-18-22 10:00AM	Best Momentum Stocks to Buy for July 18th (Zacks) -5.56%
Jul-12-22 02:54PM	Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew (Benzinga) +5.94%
07:30AM	Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
Jul-05-22 07:30AM	Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire) +17.22%
Jul-01-22 06:58AM	Will Dyne Therapeutics (NASDAQ:DYN) Spend Its Cash Wisely? (Simply Wall St.)
Jun-03-22 07:30AM	Dyne Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire) +5.05%
May-16-22 07:30AM	Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown (GlobeNewswire)
May-02-22 04:05PM	Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) +6.77%
Mar-17-22 08:45AM	selfologi Chooses Digital Technology Consulting Partner Grid Dynamics to Launch Its Cosmetic Treatment Platform (ACCESSWIRE)
Mar-10-22 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights (GlobeNewswire)
Mar-03-22 07:30AM	Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors (GlobeNewswire)
Feb-02-22 01:38PM	HC Advisors, LLC Buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, ... (GuruFocus.com) -8.68%
Jan-22-22 08:06AM	We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely (Simply Wall St.)
Jan-18-22 04:18PM	Why Shares of Dyne Therapeutics Dropped 18.1% on Tuesday (Motley Fool) -12.59%
08:00AM	Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire)
Jan-05-22 07:30AM	Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.93%
Dec-03-21 03:30PM	Dyne Therapeutics (DYN) Submits IND to FDA for DMD Candidate (Zacks) +5.94%
Dec-02-21 08:30AM	Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy (GlobeNewswire)
Nov-04-21 07:30AM	Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights (GlobeNewswire)
Oct-26-21 10:41AM	Where Do Hedge Funds Stand On Dyne Therapeutics, Inc. (DYN)? (Insider Monkey)
Oct-13-21 07:45AM	Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day (GlobeNewswire)

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McNeill Jonathan	Chief Business Officer	May 16 '24	Sale	28.27	2,774	78,420	136,634	May 17 09:03 PM
HIGH SUSANNA GATTI	Chief Operating Officer	May 16 '24	Sale	28.27	2,738	77,402	154,062	May 17 09:05 PM
Beskrovnaya Oxana	Chief Scientific Officer	May 16 '24	Sale	28.27	2,705	76,469	149,647	May 17 09:07 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	May 16 '24	Sale	28.27	2,588	73,162	116,695	May 17 09:04 PM
Farwell Wildon	Chief Medical Officer	May 16 '24	Sale	28.27	2,381	67,310	148,179	May 17 09:06 PM
Farwell Wildon	Chief Medical Officer	Mar 12 '24	Sale	25.58	1,030	26,347	150,560	Mar 12 09:58 PM
Brumm Joshua T	CEO & President	Mar 11 '24	Option Exercise	5.54	50,000	277,000	604,385	Mar 12 09:56 PM
McNeill Jonathan	Chief Business Officer	Mar 11 '24	Option Exercise	5.54	17,825	98,750	159,009	Mar 13 06:04 AM
Brumm Joshua T	CEO & President	Mar 11 '24	Sale	25.67	66,387	1,704,142	537,998	Mar 12 09:56 PM
McNeill Jonathan	Chief Business Officer	Mar 11 '24	Sale	25.50	19,601	499,842	139,408	Mar 13 06:04 AM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 11 '24	Sale	25.28	2,672	67,542	119,283	Mar 12 09:57 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Mar 11 '24	Sale	25.70	2,292	58,904	156,800	Mar 13 06:04 AM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 11 '24	Sale	25.70	2,081	53,482	152,352	Mar 12 09:42 PM
Farwell Wildon	Chief Medical Officer	Mar 11 '24	Sale	25.70	1,585	40,734	151,590	Mar 12 09:58 PM
Brumm Joshua T	CEO & President	Mar 08 '24	Option Exercise	5.54	363,343	2,012,920	917,728	Mar 12 09:56 PM
McNeill Jonathan	Chief Business Officer	Mar 08 '24	Option Exercise	5.54	90,000	498,600	231,184	Mar 13 06:04 AM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 08 '24	Option Exercise	5.54	86,252	477,836	208,207	Mar 12 09:57 PM
Brumm Joshua T	CEO & President	Mar 08 '24	Sale	25.93	363,343	9,421,634	554,385	Mar 12 09:56 PM
McNeill Jonathan	Chief Business Officer	Mar 08 '24	Sale	26.24	90,000	2,361,531	141,184	Mar 13 06:04 AM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 08 '24	Sale	26.22	86,252	2,261,465	121,955	Mar 12 09:57 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Mar 08 '24	Sale	26.67	27,199	725,344	159,092	Mar 13 06:04 AM
Farwell Wildon	Chief Medical Officer	Mar 07 '24	Sale	25.86	9,921	256,585	153,175	Mar 11 09:52 PM
Brumm Joshua T	CEO & President	Mar 07 '24	Sale	25.85	9,086	234,873	554,385	Mar 11 09:57 PM
McNeill Jonathan	Chief Business Officer	Mar 07 '24	Sale	25.85	2,434	62,919	141,184	Mar 11 09:50 PM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 07 '24	Sale	25.85	2,373	61,342	154,433	Mar 11 09:56 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 07 '24	Sale	25.85	2,273	58,757	121,955	Mar 11 09:45 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Mar 07 '24	Sale	25.85	1,591	41,127	186,291	Mar 11 09:56 PM
Brumm Joshua T	CEO & President	Mar 01 '24	Option Exercise	5.54	94,480	523,419	657,951	Mar 01 09:38 PM
McNeill Jonathan	Chief Business Officer	Mar 01 '24	Option Exercise	0.73	24,260	17,710	167,878	Mar 01 09:37 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 01 '24	Option Exercise	1.03	9,311	9,590	133,539	Mar 01 09:37 PM
Brumm Joshua T	CEO & President	Mar 01 '24	Sale	29.04	94,480	2,743,718	563,471	Mar 01 09:38 PM
Rhodes Jason P	Director	Mar 01 '24	Sale	30.05	46,534	1,398,347	847,388	Mar 05 05:08 PM
Atlas Venture Opportunity Fund	10% Owner	Mar 01 '24	Sale	30.05	29,435	884,522	1,458,691	Mar 05 05:07 PM
McNeill Jonathan	Chief Business Officer	Mar 01 '24	Sale	28.63	24,260	694,495	143,618	Mar 01 09:37 PM
Atlas Venture Opportunity Fund	10% Owner	Mar 01 '24	Sale	30.05	17,099	513,825	847,388	Mar 05 05:07 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 01 '24	Sale	28.25	9,311	262,999	124,228	Mar 01 09:37 PM
Brumm Joshua T	CEO & President	Feb 29 '24	Option Exercise	5.54	5,520	30,581	568,991	Mar 01 09:38 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Feb 29 '24	Option Exercise	1.03	3,429	3,532	127,657	Mar 01 09:37 PM
McNeill Jonathan	Chief Business Officer	Feb 29 '24	Option Exercise	0.73	4,268	3,116	147,886	Mar 01 09:37 PM
Brumm Joshua T	CEO & President	Feb 29 '24	Sale	27.50	5,520	151,800	563,471	Mar 01 09:38 PM
McNeill Jonathan	Chief Business Officer	Feb 29 '24	Sale	27.50	4,268	117,370	143,618	Mar 01 09:37 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Feb 29 '24	Sale	27.50	3,429	94,298	124,228	Mar 01 09:37 PM
Rhodes Jason P	Director	Feb 28 '24	Sale	24.84	190,920	4,741,804	864,487	Feb 28 07:15 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 28 '24	Sale	24.84	154,674	3,841,576	5,698,091	Feb 28 07:13 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 28 '24	Sale	24.84	36,246	900,228	864,487	Feb 28 07:13 PM
Rhodes Jason P	Director	Feb 27 '24	Sale	24.41	368,699	8,998,426	877,806	Feb 28 07:15 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 27 '24	Sale	24.41	298,702	7,290,088	5,852,765	Feb 28 07:13 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 27 '24	Sale	24.41	69,997	1,708,338	877,806	Feb 28 07:13 PM
Rhodes Jason P	Director	Feb 26 '24	Sale	23.72	248,219	5,886,673	903,527	Feb 28 07:15 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 26 '24	Sale	23.72	201,095	4,769,096	6,151,467	Feb 28 07:13 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 26 '24	Sale	23.72	47,124	1,117,577	903,527	Feb 28 07:13 PM
Rhodes Jason P	Director	Feb 23 '24	Sale	22.70	196,928	4,470,266	920,843	Feb 23 06:59 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 23 '24	Sale	22.70	159,542	3,621,603	6,352,562	Feb 23 06:58 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 23 '24	Sale	22.70	37,386	848,662	920,843	Feb 23 06:58 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 22 '24	Sale	22.66	119,360	2,704,698	6,512,104	Feb 23 06:58 PM
Rhodes Jason P	Director	Feb 22 '24	Sale	22.66	119,360	2,704,698	6,512,104	Feb 23 06:59 PM
Rhodes Jason P	Director	Feb 21 '24	Sale	22.57	184,501	4,164,817	6,631,464	Feb 23 06:59 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 21 '24	Sale	22.57	184,501	4,164,817	6,631,464	Feb 23 06:58 PM
Rhodes Jason P	Director	Feb 20 '24	Sale	22.72	169,539	3,852,653	6,815,965	Feb 20 06:36 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 20 '24	Sale	22.72	169,539	3,852,653	6,815,965	Feb 20 06:35 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 16 '24	Sale	23.14	162,707	3,765,040	6,985,504	Feb 20 06:35 PM
Rhodes Jason P	Director	Feb 16 '24	Sale	23.14	162,707	3,765,040	6,985,504	Feb 20 06:36 PM
Rhodes Jason P	Director	Feb 15 '24	Sale	23.89	177,906	4,249,600	7,148,211	Feb 20 06:36 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 15 '24	Sale	23.89	177,906	4,249,600	7,148,211	Feb 20 06:35 PM
Farwell Wildon	Chief Medical Officer	Feb 12 '24	Sale	25.07	5,493	137,710	163,503	Feb 14 04:27 PM
McNeill Jonathan	Chief Business Officer	Jan 26 '24	Option Exercise	0.73	20,000	14,600	163,618	Jan 26 07:48 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jan 26 '24	Option Exercise	1.03	13,000	13,390	137,228	Jan 26 07:47 PM
McNeill Jonathan	Chief Business Officer	Jan 26 '24	Sale	24.53	20,000	490,510	143,618	Jan 26 07:48 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jan 26 '24	Sale	24.34	13,000	316,420	124,228	Jan 26 07:47 PM
Farwell Wildon	Chief Medical Officer	Jan 26 '24	Sale	25.00	100	2,500	168,996	Jan 26 07:49 PM
Kersten Dirk	Director	Jan 09 '24	Buy	17.50	1,714,285	29,999,988	6,416,793	Jan 11 04:31 PM
Brumm Joshua T	CEO & President	Jan 04 '24	Option Exercise	5.16	218,536	1,127,092	803,507	Jan 04 09:49 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jan 04 '24	Option Exercise	1.03	22,674	23,354	199,259	Jan 04 09:48 PM
McNeill Jonathan	Chief Business Officer	Jan 04 '24	Option Exercise	0.73	2,009	1,467	145,627	Jan 04 09:47 PM
Brumm Joshua T	CEO & President	Jan 04 '24	Sale	18.51	218,536	4,045,958	584,971	Jan 04 09:49 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jan 04 '24	Sale	18.13	42,453	769,673	156,806	Jan 04 09:48 PM
McNeill Jonathan	Chief Business Officer	Jan 04 '24	Sale	18.04	2,009	36,242	143,618	Jan 04 09:47 PM
Brumm Joshua T	CEO & President	Jan 03 '24	Option Exercise	1.03	51,183	52,718	636,154	Jan 04 09:49 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jan 03 '24	Option Exercise	1.03	45,326	46,686	221,911	Jan 04 09:48 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jan 03 '24	Option Exercise	1.03	13,000	13,390	137,228	Jan 04 09:46 PM
McNeill Jonathan	Chief Business Officer	Jan 03 '24	Option Exercise	0.73	17,991	13,133	161,609	Jan 04 09:47 PM
Brumm Joshua T	CEO & President	Jan 03 '24	Sale	19.28	51,183	986,957	584,971	Jan 04 09:49 PM
Beskrovnaya Oxana	Chief Scientific Officer	Jan 03 '24	Sale	18.98	45,326	860,313	176,585	Jan 04 09:48 PM
McNeill Jonathan	Chief Business Officer	Jan 03 '24	Sale	18.74	17,991	337,062	143,618	Jan 04 09:47 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Jan 03 '24	Sale	18.81	13,000	244,530	124,228	Jan 04 09:46 PM
McNeill Jonathan	Chief Business Officer	Jan 02 '24	Sale	13.10	11,900	155,890	143,618	Jan 04 09:47 PM
Scalzo Richard William	See Remarks	Dec 14 '23	Sale	12.02	2,376	28,560	124,228	Dec 14 04:59 PM
Farwell Wildon	Chief Medical Officer	Dec 12 '23	Sale	10.55	978	10,318	169,096	Dec 12 05:33 PM
Brumm Joshua T	See Remarks	Dec 11 '23	Sale	10.72	7,585	81,311	584,971	Dec 12 05:33 PM
Farwell Wildon	Chief Medical Officer	Dec 11 '23	Sale	10.72	1,688	18,095	170,074	Dec 12 05:33 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Dec 11 '23	Sale	10.72	1,616	17,324	187,882	Dec 12 05:34 PM
Beskrovnaya Oxana	Chief Scientific Officer	Dec 11 '23	Sale	10.72	1,467	15,726	176,585	Dec 12 05:32 PM
Scalzo Richard William	See Remarks	Dec 11 '23	Sale	10.72	1,380	14,794	126,604	Dec 12 05:35 PM
McNeill Jonathan	Chief Business Officer	Dec 11 '23	Sale	10.72	1,245	13,346	155,518	Dec 12 05:34 PM
Scalzo Richard William	See Remarks	Dec 06 '23	Sale	12.01	1,872	22,483	127,984	Dec 06 06:13 PM
Scalzo Richard William	See Remarks	Dec 04 '23	Sale	12.01	681	8,179	129,856	Dec 06 06:13 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Nov 02 '23	Sale	7.40	9,939	73,549	94,605	Nov 02 05:16 PM
Brumm Joshua T	See Remarks	Sep 18 '23	Sale	9.41	12,032	113,221	233,679	Sep 20 04:47 PM
HIGH SUSANNA GATTI	Chief Operating Officer	Sep 18 '23	Sale	9.41	2,672	25,144	104,544	Sep 20 04:48 PM
Beskrovnaya Oxana	Chief Scientific Officer	Sep 18 '23	Sale	9.41	1,436	13,513	84,334	Sep 20 04:47 PM

Open in Screener

XLO

Xilio Therapeutics Inc

May 17 • 04:00PM ET

1.14

Dollar change +0.06
Percentage change 5.56	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

XLO Xilio Therapeutics Inc daily Stock Chart

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-2.57	Insider Own	36.24%	Shs Outstand	27.61M	Perf Week	-3.39%
Market Cap	42.08M	Forward P/E	-	EPS next Y	-0.94	Insider Trans	3.72%	Shs Float	23.53M	Perf Month	-10.94%
Income	-70.96M	PEG	-	EPS next Q	-0.23	Inst Own	11.13%	Short Float	1.94%	Perf Quarter	86.58%
Sales	0.00M	P/S	-	EPS this Y	49.82%	Inst Trans	-4.43%	Short Ratio	0.37	Perf Half Y	-14.93%
Book/sh	0.75	P/B	1.53	EPS next Y	32.62%	ROA	-73.11%	Short Interest	0.46M	Perf Year	-63.58%
Cash/sh	0.92	P/C	1.24	EPS next 5Y	-	ROE	-128.37%	52W Range	0.49 - 3.25	Perf YTD	107.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-44.91%	ROI	-211.02%	52W High	-64.92%	Beta	-0.03
Dividend TTM	-	Quick Ratio	2.19	Sales past 5Y	0.00%	Gross Margin	-	52W Low	132.65%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	2.19	EPS Y/Y TTM	21.31%	Oper. Margin	0.00%	RSI (14)	51.07	Volatility	10.18% 11.20%
Employees	73	Debt/Eq	0.35	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.50	Target Price	5.50
Option/Short	No / Yes	LT Debt/Eq	0.31	EPS Q/Q	25.34%	Payout	-	Rel Volume	0.09	Prev Close	1.08
Sales Surprise	-100.00%	EPS Surprise	-463.64%	Sales Q/Q	-	Earnings	May 14 BMO	Avg Volume	1.24M	Price	1.14
SMA20	1.69%	SMA50	8.69%	SMA200	-19.26%	Trades		Volume	116,563	Change	5.56%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-21-22	Initiated	Chardan Capital Markets	Buy	$7
Jan-10-22	Initiated	H.C. Wainwright	Buy	$36
Nov-16-21	Initiated	Raymond James	Outperform	$31
Nov-16-21	Initiated	Morgan Stanley	Overweight	$32
Nov-16-21	Initiated	Guggenheim	Buy	$40
Nov-16-21	Initiated	Cowen	Outperform

May-14-24 01:54PM	XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results (GlobeNewswire)
Apr-16-24 09:14AM	Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why (Zacks)
Apr-01-24 10:53PM	XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +41.67%
04:05PM	Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
11:10AM	Loading…
Mar-28-24 11:10AM	Why Is Xilio Therapeutics (XLO) Stock up 168% Today? (InvestorPlace) +69.01%
07:05AM	Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing (GlobeNewswire)
07:00AM	Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program (GlobeNewswire)
06:45AM	Gilead bets on Xilio cancer drug as biotech restructures (BioPharma Dive)
Feb-28-24 04:01PM	Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +5.60%
Jan-31-24 04:01PM	Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-08-24 07:30AM	Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies (GlobeNewswire)
Dec-07-23 07:30AM	Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data (GlobeNewswire)
Nov-09-23 04:01PM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results (GlobeNewswire) -13.04%
Nov-03-23 12:00PM	Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors (GlobeNewswire)
09:15AM	Loading…
Oct-31-23 09:15AM	Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting (GlobeNewswire)
Sep-27-23 05:02PM	Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire)
Sep-05-23 08:30AM	Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer (GlobeNewswire)
07:30AM	Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-18-23 04:27AM	Q2 2023 Xilio Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 04:05PM	Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer (GlobeNewswire)
May-25-23 05:01PM	Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors (GlobeNewswire)
May-09-23 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-03-23 04:05PM	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-02-23 04:05PM	Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -7.37%
Feb-27-23 07:30AM	Xilio Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.72%
Feb-16-23 07:30AM	Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit (GlobeNewswire)
Feb-02-23 07:30AM	Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day (GlobeNewswire)
Jan-26-23 05:30AM	Institutions profited after Xilio Therapeutics, Inc.'s (NASDAQ:XLO) market cap rose US$33m last week butprivate equity firms profited the most (Simply Wall St.)
09:45AM	Loading…
Jan-25-23 09:45AM	These 2 Strong Buy Penny Stocks Are on Track for Massive Gains, Say Analysts (TipRanks) +36.92%
Nov-23-22 07:30AM	Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12 (GlobeNewswire) +7.94%
Nov-09-22 07:30AM	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-04-22 07:30AM	Xilio Therapeutics to Present at Cowen 6th Annual IO Next Summit (GlobeNewswire)
Sep-22-22 04:05PM	Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference (GlobeNewswire)
Sep-15-22 04:05PM	Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors (GlobeNewswire) +15.38%
Sep-06-22 04:05PM	Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire) +8.21%
Aug-11-22 09:41AM	Is Xilio Therapeutics (NASDAQ:XLO) In A Good Position To Invest In Growth? (Simply Wall St.)
Aug-09-22 07:30AM	Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results (GlobeNewswire) -26.22%
Jun-16-22 07:30AM	Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President (GlobeNewswire)
May-18-22 07:30AM	Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) -9.56%
May-17-22 07:30AM	Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer (GlobeNewswire) -5.18%
May-12-22 07:30AM	Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results (GlobeNewswire)
Apr-07-22 06:30AM	Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-01-22 06:30AM	Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) -7.56%
Feb-28-22 06:30AM	Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference (GlobeNewswire) -10.42%
Feb-07-22 05:38PM	RiverVest Venture Management LLC Buys Xilio Therapeutics Inc (GuruFocus.com)
Feb-03-22 06:30AM	Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day (GlobeNewswire)
Jan-25-22 10:27AM	Are Institutions Heavily Invested In Xilio Therapeutics, Inc.'s (NASDAQ:XLO) Shares? (Simply Wall St.)
Jan-20-22 07:30AM	Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors (GlobeNewswire) +9.79%
Jan-06-22 07:30AM	Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors (GlobeNewswire)
Dec-02-21 07:30AM	Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results (GlobeNewswire) -12.46%
Nov-12-21 07:00AM	Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting (GlobeNewswire) -6.69%
Oct-27-21 07:45AM	4 Stocks Insiders Are Buying (Benzinga)
Oct-26-21 04:05PM	Xilio Therapeutics Announces Closing of Initial Public Offering (GlobeNewswire)

Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GILEAD SCIENCES, INC.	10% Owner	Apr 02 '24	Buy	0.76	485,250	368,790	7,345,473	Apr 03 06:50 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 08 '24	Sale	0.64	733	469	2,019,563	Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 08 '24	Sale	0.64	267	171	734,546	Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.	10% Owner	Jan 12 '24	Sale	0.83	1,540	1,278	2,020,296	Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.	10% Owner	Jan 12 '24	Sale	0.83	560	465	734,813	Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.	10% Owner	Jan 11 '24	Sale	0.87	1,566	1,362	2,021,836	Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.	10% Owner	Jan 11 '24	Sale	0.87	569	495	735,373	Jan 16 06:16 PM

Open in Screener

THRD

Third Harmonic Bio Inc

May 17 • 04:00PM ET

13.86

Dollar change -0.36
Percentage change -2.57	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

THRD Third Harmonic Bio Inc daily Stock Chart

Held by: IWM VTI IWN VXF IBB SCHA VTWO IWC IWV VTWV

Index	RUT	P/E	-	EPS (ttm)	-0.74	Insider Own	63.11%	Shs Outstand	40.10M	Perf Week	16.51%
Market Cap	567.77M	Forward P/E	-	EPS next Y	-1.69	Insider Trans	-0.20%	Shs Float	15.11M	Perf Month	21.30%
Income	-29.59M	PEG	-	EPS next Q	-0.32	Inst Own	39.80%	Short Float	13.58%	Perf Quarter	37.69%
Sales	0.00M	P/S	-	EPS this Y	-64.66%	Inst Trans	-	Short Ratio	13.51	Perf Half Y	118.35%
Book/sh	6.55	P/B	2.12	EPS next Y	-31.81%	ROA	-10.53%	Short Interest	2.05M	Perf Year	218.00%
Cash/sh	6.42	P/C	2.16	EPS next 5Y	-	ROE	-10.84%	52W Range	4.33 - 14.23	Perf YTD	26.39%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-11.10%	52W High	-2.57%	Beta	3.02
Dividend TTM	-	Quick Ratio	66.10	Sales past 5Y	0.00%	Gross Margin	-	52W Low	220.16%	ATR (14)	0.76
Dividend Ex-Date	-	Current Ratio	66.10	EPS Y/Y TTM	32.17%	Oper. Margin	0.00%	RSI (14)	70.82	Volatility	6.98% 6.31%
Employees	30	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.00	Target Price	13.50
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	50.98%	Payout	-	Rel Volume	0.41	Prev Close	14.23
Sales Surprise	-	EPS Surprise	164.50%	Sales Q/Q	-	Earnings	May 15 BMO	Avg Volume	151.82K	Price	13.86
SMA20	17.62%	SMA50	29.20%	SMA200	58.95%	Trades		Volume	62,843	Change	-2.57%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-16-22	Downgrade	Jefferies	Buy → Hold	$30 → $3.60
Dec-15-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$5
Oct-10-22	Initiated	Morgan Stanley	Overweight	$34
Oct-10-22	Initiated	Jefferies	Buy	$30
Oct-10-22	Initiated	Cowen	Outperform

May-15-24 12:52PM	THRD Stock Earnings: Third Harmonic Bio Beats EPS for Q1 2024 (InvestorPlace)
08:05AM	Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-10-24 07:02PM	Insider Sale: CEO Natalie Holles Sells Shares of Third Harmonic Bio Inc (THRD) (GuruFocus.com)
Apr-15-24 07:00PM	Third Harmonic Bio Inc CEO Natalie Holles Sells 13,558 Shares (GuruFocus.com)
Mar-28-24 08:30AM	Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors (GlobeNewswire)
09:02PM	Loading…
Mar-26-24 09:02PM	Third Harmonic Bio Inc (THRD) Reports Decreased Net Loss in Q4, Aligns with Analyst Projections (GuruFocus.com)
01:53PM	THRD Stock Earnings: Third Harmonic Bio Beats EPS for Q4 2023 (InvestorPlace)
08:05AM	Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 04:00PM	Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Jan-04-24 08:00AM	Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update (GlobeNewswire)
Dec-29-23 12:00PM	Are You Looking for a Top Momentum Pick? Why Third Harmonic Bio, Inc. (THRD) is a Great Choice (Zacks)
Dec-08-23 01:05PM	Insider Sell Alert: Third Harmonic Bio Inc's Julie Person Divests 12,863 Shares (GuruFocus.com) +5.40%
Nov-09-23 09:30AM	Third Harmonic Bio Inc (THRD) Reports Q3 2023 Financial Results and Continues Progress Towards ... (GuruFocus.com)
08:30AM	Third Harmonic Bio Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-31-23 08:30AM	Third Harmonic Bio Announces Leadership Changes (GlobeNewswire) -9.22%
08:30AM	Loading…
Aug-31-23 08:30AM	Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-10-23 08:10AM	Third Harmonic Bio Announces Second Quarter 2023 Financial Results (GlobeNewswire) -7.00%
Jul-26-23 09:40AM	Target downgraded, Spotify upgraded: Wall Street's top analyst calls (The Fly) +9.11%
Jul-25-23 08:30AM	Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335 (GlobeNewswire) +5.26%
Jun-09-23 08:04AM	10 Struggling IPOs To Buy For The Long-Term (Insider Monkey)
May-24-23 11:02AM	We Think Third Harmonic Bio (NASDAQ:THRD) Can Afford To Drive Business Growth (Simply Wall St.)
May-11-23 05:00PM	Third Harmonic Bio Announces First Quarter 2023 Financial Results (GlobeNewswire) -7.32%
Mar-29-23 08:05AM	Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results (GlobeNewswire)
Dec-23-22 06:32AM	Daily Vickers Top Buyers & Sellers for 12/23/2022 (Argus Research)
Dec-22-22 05:41AM	The Petri Dish: Third Harmonic axes lead program; bluebird moves forward with 3rd drug (American City Business Journals)
Dec-15-22 10:10AM	Third Harmonic Bio Stock Plummets After Trial Discontinuation On Safety Concerns (Benzinga) -78.28%
09:53AM	Third Harmonic Plunges Almost 80% After Ending Study for Skin-Inflammation Drug (Bloomberg)
08:49AM	We Think Third Harmonic Bio (NASDAQ:THRD) Can Afford To Drive Business Growth (Simply Wall St.)
08:22AM	Third Harmonic's stock falls 75% after discontinuing clinical trial (MarketWatch)
07:00AM	Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria (GlobeNewswire)
04:05PM	Loading…
Nov-21-22 04:05PM	Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference (GlobeNewswire)
Nov-09-22 04:15PM	Third Harmonic Bio Announces Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 08:01AM	These Bases, Breakouts And Buy Zones Offer Fresh Opportunities (Investor's Business Daily) -6.14%
Sep-19-22 04:10PM	Third Harmonic Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire) -5.56%
Sep-15-22 11:41AM	Third Harmonic Bio stock opens more than 20% above IPO price (MarketWatch)
07:58AM	Third Harmonic Bio prices upsized IPO at $17 a share, midpoint of range (MarketWatch)

Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Holles Natalie C.	CEO	May 09 '24	Option Exercise	4.20	20,222	84,932	1,239,058	May 10 04:04 PM
Holles Natalie C.	CEO	May 09 '24	Sale	12.18	20,222	246,300	1,218,836	May 10 04:04 PM
Holles Natalie C.	CEO	Apr 11 '24	Option Exercise	4.20	13,558	56,944	1,232,394	Apr 15 04:14 PM
Holles Natalie C.	CEO	Apr 11 '24	Sale	12.19	13,558	165,214	1,218,836	Apr 15 04:14 PM
Person Julie	CHIEF ADMINISTRATIVE OFFICER	Apr 04 '24	Option Exercise	4.20	1,107	4,649	1,107	Apr 08 05:21 PM
Person Julie	CHIEF ADMINISTRATIVE OFFICER	Apr 04 '24	Sale	10.00	1,107	11,070	0	Apr 08 05:21 PM
Person Julie	Chief Administrative Officer	Dec 05 '23	Option Exercise	4.20	12,863	54,025	12,863	Dec 07 04:04 PM
Conner Edward R.	Chief Medical Officer	Dec 05 '23	Option Exercise	4.20	4,790	20,118	4,790	Dec 07 04:03 PM
Person Julie	Chief Administrative Officer	Dec 05 '23	Sale	10.30	12,863	132,484	0	Dec 07 04:04 PM
Conner Edward R.	Chief Medical Officer	Dec 05 '23	Sale	10.03	4,790	48,062	0	Dec 07 04:03 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

DYN

Dyne Therapeutics Inc

XLO

Xilio Therapeutics Inc

THRD

Third Harmonic Bio Inc

Upgrade your FINVIZ experience